Recruiting

Testing a natural enzyme treatment for three chronic post-infection conditions

Plain-English translation of NCT06511050 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing lumbrokinase, a natural enzyme derived from earthworms, to see if it can help adults who are struggling with long-lasting symptoms from three different conditions: Long COVID (ongoing symptoms after COVID-19), post-treatment Lyme disease syndrome (persistent symptoms after Lyme disease treatment), or myalgic encephalomyelitis/chronic fatigue syndrome (severe fatigue and related symptoms). Researchers want to understand whether this medication is safe and might help people feel better when they take it twice daily for 6 weeks.

Many people experience chronic, debilitating symptoms long after an acute infection or illness, and current treatment options are limited. This trial exists to explore whether this medication—which has been used in some parts of the world—might help restore quality of life for people living with these exhausting, long-term conditions.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with only one of the three conditions being studied: Long COVID, post-treatment Lyme disease syndrome, or myalgic encephalomyelitis/chronic fatigue syndrome
you have experienced a significant drop in your quality of life since your initial infection or illness (your health rating is now 70 or lower, but was 80 or higher before)
for Long COVID: you had confirmed or suspected COVID-19 at least 3 months ago and have a physician's diagnosis of Long COVID
for Lyme disease: you have medical documentation of Lyme disease and meet established diagnostic criteria for post-treatment syndrome

You likely don't qualify if…

you are currently taking blood-thinning medications or have a bleeding disorder
you are pregnant or breastfeeding
you have been diagnosed with more than one of the three studied conditions

What participation looks like

If you join this study, you will take capsules of the medication twice per day for 6 weeks. You will visit the research site at the beginning of the study and again at the end to have your health and symptoms checked. The researchers will ask you questions about how you're feeling and may collect some basic health information to see whether the treatment has helped improve your quality of life.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

United States

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York